Procter & Gamble and Qualyst Transporter Solutions, LLC Collaborate on an Herb-Drug Interaction Study Publication: Study demonstrates the effectiveness of the Qualyst in vitro hepatic model to predict CYP450 induction and inhibition interactions observed in the clinic
Durham, N.C. (August 15, 2017) – Qualyst Transporter Solutions, LLC collaborated with Procter & Gamble Co. (P&G) to publish “Prediction of Clinically Relevant Herb-Drug Clearance Interactions Using Sandwich-Cultured Human Hepatocytes: Schisandra spp. Case Study” in Drug Metabolism and Disposition. 2017; 45(9) .
Clinical studies have shown that Schisandra sphenanthera extract (SSE) therapy reduced midazolam (MDZ) clearance in humans. A study sponsored by Procter & Gamble Co., showed that the Qualyst in vitro human hepatic model accurately predicted (e.g. net effect and relative strength) the clinically-observed herb-drug, (SSE-MDZ) interaction.
Dr. Jonathan Jackson, who led the research team at Qualyst explained, “Our model uses Transporter Certified™ human hepatocytes in sandwich-culture to provide a fully integrated hepatic cell system that maintains drug clearance and regulatory pathways necessary for a quantitative assessment of herb-drug interaction potential. Compared to conventional, transporter-deficient systems, our model consistently demonstrates high in vitro-in vivo correlation making it superior for CYP450 induction studies, and any studies in which it is important to have human physiologically-relevant results.”
“This novel approach allows us to study the interplay between constituents of the complex mixtures that herbal extracts represent”, said Dr. Amy Roe, Principal Toxicologist at P&G. “Our work is a proof of concept using an experimental design that captures the major clinically-relevant hepatic pathways to allow for improved predictions of herb-drug interactions in humans.”
About Procter & Gamble Co
See “Who We Are” on the Procter & Gamble web site.
About Qualyst Transporter Solutions, LLC
See “Company” on the Qualyst web site.
Qualyst Transporter Solutions, LLC (Qualyst) provides in vitro hepatic models to predict the effect of drugs and other compounds on the human liver. Qualyst’s in vitro models integrate hepatic uptake, metabolism, regulation, and efflux and demonstrate superior in vitro-in vivo correlation compared to conventional systems. Qualyst’s proprietary technology, products, and services are used by leading pharmaceutical, nutrition, cosmetics and consumer products, and chemical companies to provide clinically-relevant answers to liver-related questions, and to address regulatory concerns about their products.